ангиотензин转化酶抑制剂:用于控制血压的治疗选择,与延迟认知处理速度相关
Michel Ferreira Machado1, Henrique Cotchi Simbo Muela2, Valeria Aparecida Costa-Hong2
1Department of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil. michelfmachado83@gmail.com.
Journal of human hypertension
|October 4, 2024
概括
抗高血压治疗对于预防认知能力下降至关重要. 这项研究发现,高血压患者的认知表现较差,并且特定的抗高血压药物如ACE抑制剂对处理速度产生了负面影响.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 高血压是认知能力下降的重要危险因素.
- 抗高血压治疗 (AT) 对于缓解与高血压相关的认知障碍至关重要.
- 不同抗高血压药物 (AHD) 对认知表现 (CP) 的具体影响需要进一步调查.
研究的目的:
- 为了比较非高血压志愿者和高血压患者之间的认知表现.
- 评估认知表现与使用特定抗高血压药物的相关性.
- 探索AT在认知上的机制,除了降低血压.
主要方法:
- 一项观察性研究涉及三个组:非高血压 (NH),受控高血压和不受控制的高血压.
- 一个神经心理学电池被用来评估认知领域,性能转化为z分数.
- 线性回归模型分析了AHD使用与认知表现,特别是处理速度 (PS) 之间的关联.
主要成果:
- 高血压组年龄较大,与NH个体相比,在情节性记忆,语言和处理速度方面表现出较差的CP.
- ангиотензин转化酶抑制剂 (ACEi) 和 ангиотензин受体阻断剂 (ARB) 是最常见的AHDs.
- 在PS和ACEi使用之间发现了负相关性,这表明药物对认知有特定的影响.
结论:
- 抗高血压治疗对认知的影响不仅仅是降低血压,而AHD机制也发挥了作用.
- 适应AT疗法可能会带来额外的认知益处,即使在没有明显认知障碍的患者中也是如此.
- 对AHD机制的进一步研究是有必要的,以优化高血压患者的认知结果.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
490
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
490
01:25Antihypertensive Drugs: Direct Renin Inhibitors
506
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
506
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
597
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
597
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
3
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
3
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137